Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citicoline eye drops for visual field preservation in open-angle glaucoma
2022-502273-42-00Phase 3Authorised
- Sponsor
- Omikron Italia
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG), pseudoexfoliation glaucoma (PXG) and pigmentary glaucoma (PG) comparing Citicoline eye drops with Placebo eye drops (2 arms). Planned start Nov 2023; status: authorised.
02
Drugs
citicoline
03
Conditions
open-angle glaucoma (OAG)pseudoexfoliation glaucoma (PXG)pigmentary glaucoma (PG)
Beyond the preview
Go deeper on 2022-502273-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502273-42-00.